Your session is about to expire
← Back to Search
Diagnostic Test
Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR for Coronary Artery Disease
N/A
Recruiting
Led By Carlo De Cecco, MD, PhD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 (day of scans)
Awards & highlights
Study Summary
This trial is comparing two different ways of measuring heart function: one using CT scans and one using PET scans. The goal is to see if CT scans are as accurate as PET scans.
Who is the study for?
This trial is for individuals who need a CT scan to check for coronary artery disease and are willing to follow the study's procedures. They must not be pregnant, nursing, or have taken certain diabetes medications recently. People with implanted heart devices, severe allergies to contrast material used in scans, kidney issues, low blood pressure, or specific heart rhythm problems cannot participate.Check my eligibility
What is being tested?
The MATCH Investigation aims to compare two types of heart imaging tests: CT scans that measure blood flow and blockages in the heart arteries (CT-MPI and CT-FFR) against PET scans known as PET-MPI which is considered the gold standard.See study design
What are the potential side effects?
Possible side effects include allergic reactions to contrast dye or stress agents used during imaging like Regadenoson. There might also be discomfort from lying still during scanning and exposure to radiation typical of medical imaging.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 (day of scans)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 (day of scans)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Coronary Flow
Detection of Coronary Stenosis
Detection of Myocardial Perfusion Abnormalities
+2 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Three imaging techniques: PET-MPI, CT-MPI, and CT-FFRExperimental Treatment4 Interventions
Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CT-FFR
2022
N/A
~520
Regadenoson
2012
Completed Phase 4
~5300
Find a Location
Who is running the clinical trial?
Emory UniversityLead Sponsor
1,640 Previous Clinical Trials
2,560,676 Total Patients Enrolled
29 Trials studying Coronary Artery Disease
11,325 Patients Enrolled for Coronary Artery Disease
Siemens Medical SolutionsIndustry Sponsor
24 Previous Clinical Trials
3,708 Total Patients Enrolled
3 Trials studying Coronary Artery Disease
604 Patients Enrolled for Coronary Artery Disease
Carlo De Cecco, MD, PhDPrincipal InvestigatorEmory University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am referred for a CT scan to check my heart's blood flow.
Research Study Groups:
This trial has the following groups:- Group 1: Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger